BLOG: Outlook for Allergan destined to change
Read more from Darrell E. White
Admit it. You went to ASCRS expecting to join your colleagues in the act of righteous indignation at the CMS data dump of physician Medicare income. I sure did. Boy, did THAT change fast when the news of Valeant and William Ackman teaming up to make a play for Allergan hit the front page of The Wall Street Journal on Tuesday before the meeting! I don’t know about you, but the only time the whole CMS nonsense came up was when another doc made the same observation that I just did.
What do you think? One of our biggest, most important pharmaceutical companies, at least as far as anterior segment surgeons and dry eye docs are concerned, is now “in play.” If history serves, and it always does, Allergan as we know it is going to change. Get the whole story